10-Q: Exelixis Reports Strong Q1 2025 Results Driven by CABOMETYX Sales Growth

Sentiment:

Quarterly Report 13 May 2025 4:14 PM

Exelixis announces a significant increase in net product revenues and total revenues for the first quarter of 2025, primarily driven by the continued success of CABOMETYX.

Better than expectedNet product revenues increased by 36% year-over-year, reaching $513.3 million in Q1 2025.Total revenues grew by 31% to $555.4 million in Q1 2025.Net income surged to $159.6 million in Q1 2025, a substantial increase from $37.3 million in Q1 2024.

Summary

Exelixis reported net product revenues of $513.3 million for Q1 2025, a 36% increase compared to $378.5 million in Q1 2024.
Total revenues for Q1 2025 reached $555.4 million, up 31% from $425.2 million in the same period last year.
The increase in net product revenues was primarily due to a 25% increase in CABOMETYX unit sales and a 9% increase in the average net selling price.
Research and development expenses decreased to $212.2 million in Q1 2025 from $227.7 million in Q1 2024.
Selling, general, and administrative expenses increased to $137.2 million in Q1 2025 from $114.0 million in Q1 2024.
Net income for Q1 2025 was $159.6 million, or $0.57 per share basic and $0.55 per share diluted, compared to $37.3 million, or $0.12 per share basic and diluted, for Q1 2024.
The company repurchased 14.2 million shares of common stock for $494.5 million as of March 31, 2025, with $505.5 million remaining available for future repurchases.
Exelixis anticipates initiating a phase 3 pivotal trial for zanzalintinib in advanced NET in the first half of 2025.
The FDA approved CABOMETYX for previously treated advanced NET in March 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and strategic advancements. The company is growing revenues, managing expenses, and advancing its pipeline. However, there are risks related to competition, regulation, and potential generic entry.

Positives

Significant revenue growth driven by CABOMETYX sales.
Substantial increase in net income.
FDA approval of CABOMETYX for a new indication (previously treated advanced NET).
Advancement of zanzalintinib program with planned phase 3 trial.
Active stock repurchase program, indicating confidence in the company's financial position.

Negatives

Selling, general, and administrative expenses increased, potentially impacting profitability.
Research and development expenses decreased, which could impact future growth.

Risks

Dependence on the commercial success of CABOMETYX.
Competition from other cancer therapies.
Potential challenges in obtaining and maintaining coverage and reimbursement for CABOMETYX.
Risk of generic competition from ANDA filers like MSN and Sun, and 505(b)(2) filers like Azurity.
Uncertainties in the regulatory approval process for new indications and product candidates.
Potential impact of healthcare reforms and drug pricing regulations.
Potential impact of U.S. tariff announcements.

Future Outlook

Exelixis anticipates that net product revenues may increase for the remainder of 2025 due to the recent FDA approval of CABOMETYX for patients with previously treated advanced NET and expects to progress up to two new development candidates into preclinical development later in 2025.

Management Comments

We will continue to face numerous challenges and risks that may impact our ability to execute on our business objectives.
For the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies.

Industry Context

The report highlights the competitive landscape of cancer therapies and the importance of maintaining a competitive position. It also addresses the impact of healthcare policies and regulations, including the Inflation Reduction Act, on drug pricing and reimbursement.

Comparison to Industry Standards

The report does not provide specific comparisons to industry standards or benchmarks.
However, it mentions collaborations with major pharmaceutical companies like Bristol-Myers Squibb, Roche, and Merck, indicating a strategy of partnering with industry leaders.
The company's focus on developing novel therapies and combination regimens aligns with current trends in oncology drug development.

Legal Proceedings

MSN ANDA Litigation: Ongoing patent infringement lawsuits against MSN Pharmaceuticals regarding generic versions of CABOMETYX tablets.
Sun ANDA Litigation: Patent infringement lawsuit against Sun Pharmaceutical Industries Ltd. regarding a generic version of CABOMETYX tablets.
Biocon ANDA Litigation: Patent infringement lawsuit against Biocon Pharma Limited regarding a generic version of CABOMETYX tablets.
Azurity 505(b)(2) NDA Litigation: Patent infringement lawsuit against Azurity Pharmaceuticals, Inc. regarding cabozantinib (S)-malate tablets.
Azurity filed a petition seeking inter partes review of U.S. Patent No. 11,298,349 (pharmaceutical composition) at the United States Patent and Trademark Office.
Azurity filed a petition seeking inter partes review of U.S. Patent No. 12,128,039 (low impurity) at the United States Patent and Trademark Office.
Exelixis received notice letters (Notices) from the West Virginia Board of Pharmacy (WV Board) of complaints filed against us for purported violations of laws related to distribution of drugs to 340B facilities (West Virginia Code 60A-8-6a (WV Statute)).

Stakeholder Impact

Shareholders: Positive impact due to increased revenues, net income, and stock repurchase program.
Employees: Potential for continued employment and career growth due to company's financial stability and pipeline development.
Patients: Potential for new treatment options through the development of zanzalintinib and other pipeline candidates.
Customers: Continued access to CABOMETYX and potential for new indications.
Collaboration Partners: Continued collaboration on the development and commercialization of cabozantinib and other therapies.

Next Steps

Initiate a phase 3 pivotal trial for zanzalintinib in advanced NET in the first half of 2025.
Continue clinical trials for zanzalintinib, XL309, XB010, and XB628.
Progress up to two new development candidates into preclinical development later in 2025.
Continue to engage in pipeline expansion initiatives.

Key Dates

Date	Description
2016-04	FDA first approved CABOMETYX in the U.S. as a monotherapy for previously treated patients with advanced RCC.
2017-01	Exelixis entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib.
2017-12	FDA approved CABOMETYX for previously untreated patients with advanced RCC.
2019-01	FDA approved CABOMETYX for the treatment of patients with HCC previously treated with sorafenib.
2019-09	Exelixis received a notice letter regarding an ANDA submitted to the FDA by MSN Pharmaceuticals, Inc.
2021-01	CABOMETYX label was expanded to include first-line advanced RCC in combination with nivolumab.
2021-01-01	Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.
2021-09	FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC.
2022-06	Exelixis and MSN stipulated that MSNs submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, if those claims are not found to be invalid.
2022-06-21	The Delaware District Court entered an order that MSNs submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, if those claims are not found to be invalid.
2022-08	Former President Biden signed the IRA.
2022-10	The two lawsuits comprising this litigation (collectively referred to as MSN II), numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated.
2023-08	Exelixis announced positive top-line results from CONTACT-02, a phase 3 pivotal trial.
2023-09	The final analysis for CONTACT-02, which was presented during the GU Tumours Proffered Paper Session at the European Society for Medical Oncology Congress, showed a trend that favored the combination of cabozantinib and atezolizumab but was not statistically significant.
2023-11	CMS released final guidance on the Medicare Part D Manufacturer Discount Program.
2023-12	Exelixis initiated STELLAR-305, a phase 2/3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab.
2024-08	Exelixis' Board of Directors authorized a stock repurchase program to acquire up to $500.0 million of its outstanding common stock before December 31, 2025.
2024-10	Exelixis announced the initiation of a phase 1 clinical trial evaluating XL495, an inhibitor of PKMYT1.
2024-10-15	The Delaware District Court issued a ruling rejecting MSNs invalidity challenge to each of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015.
2024-10-23	The Delaware District Court entered final judgment that, should the FDA ultimately approve MSNs ANDA, the effective date of any such approval of MSNs ANDA shall not be a date earlier than January 15, 2030, the expiration date of each of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, subject to our potential additional regulatory exclusivity.
2024-11-22	MSN noticed an appeal to the Court of Appeals for the Federal Circuit.
2024-11-26	Exelixis noticed a cross-appeal.
2025-01	Exelixis presented preliminary results from a randomized expansion cohort of patients with metastatic CRC from STELLAR-001, and results from a subgroup analysis of patients in the epNET cohort with advanced gastrointestinal NET in CABINET, at the ASCO GI 2025.
2025-01	CMS announced the list of 15 drugs selected for the second round of drug pricing evaluations.
2025-02	Exelixis announced final five-year follow-up results from the CheckMate -9ER trial at the ASCO Genitourinary Cancers Symposium.
2025-02	Exelixis announced that its Board of Directors had authorized the repurchase of up to $500 million of its common stock before December 31, 2025.
2025-03	FDA Approval of CABOMETYX for patients with previously treated advanced NET.
2025-03	FDA cleared Exelixis' Investigational New Drug (IND) application for XB628.
2025-03	Exelixis received a notice letter regarding an ANDA submitted to the FDA by Biocon Pharma Limited (Biocon), requesting approval to market a generic version of CABOMETYX tablets.
2025-03	Exelixis received a notice letter regarding a 505(b)(2) New Drug Application (505(b)(2)) submitted to the FDA by Azurity Pharmaceuticals, Inc. (Azurity), requesting approval to market cabozantinib ( S )-malate tablets.
2025-03-11	Exelixis filed our preliminary response to Azurity's petition seeking inter partes review of U.S. Patent No. 11,298,349 (pharmaceutical composition) at the United States Patent and Trademark Office.
2025-03-17	Exelixis received notice letters (Notices) from the West Virginia Board of Pharmacy (WV Board) of complaints filed against us for purported violations of laws related to distribution of drugs to 340B facilities (West Virginia Code 60A-8-6a (WV Statute)).
2025-03-19	Exelixis filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 12,128,039 arising from MSNs further amendment of its ANDA filing with the FDA.
2025-04-01	MSN filed its Opening Brief arguing that the asserted claims of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015, and 11,298,349 are invalid.
2025-04-04	Exelixis filed a complaint in the Delaware District Court for patent infringement against Sun asserting infringement of U.S. Patent No. 12,128,039 arising from Suns amendment of its ANDA filing with the FDA.
2025-04-10	MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 12,128,039 are invalid, unenforceable, and not infringed.
2025-04-11	Exelixis filed a complaint in the Delaware District Court for patent infringement against Biocon asserting infringement of U.S. Patent Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, and 12,128,039.
2025-04-18	Exelixis filed a complaint in the Delaware District Court for patent infringement against Azurity asserting infringement of U.S. Patent Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, 11,298,349, and 12,128,039.
2025-04-24	Exelixis filed our First Amended Complaint alleging infringement of the same patents.
2025-04-24	Exelixis received notice letters (Notices) from the West Virginia Board of Pharmacy (WV Board) of complaints filed against us for purported violations of laws related to distribution of drugs to 340B facilities (West Virginia Code 60A-8-6a (WV Statute)).
2025-05-12	The current U.S. Presidential administration published an executive order that expressed support for equalizing the prices paid for drugs in the United States and other developed countries by employing an MFN approach to drug pricing.
2025-07-11	Exelixis' response (including any cross-appeal) is currently due.
2026-11-02	Trial in this matter has been scheduled.

Keywords

CABOMETYX, zanzalintinib, Exelixis, revenues, clinical trials, FDA approval, oncology, NET, stock repurchase, financial results

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.